|

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

RECRUITINGPhase 2Sponsored by Patrick Lao
Actively Recruiting
PhasePhase 2
SponsorPatrick Lao
Started2020-11-17
Est. completion2026-05-31
Eligibility
Age50 Years+
Healthy vol.Accepted
Locations1 site

Summary

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion criteria:

1. Age 50 and over at time of screening.
2. At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis.
3. Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.
4. Subjects unable to provide informed consent must have a surrogate decision maker.
5. Written and oral fluency in English or Spanish.
6. Able to participate in all scheduled evaluations and to complete all required tests and procedures.
7. In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.

Exclusion criteria:

1. Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).
2. Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.
3. Contraindication to MRI scanning.
4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.
6. Exact medication exclusions are up to the discretion of the PI in consultation with the MD liaison.

Conditions2

Alzheimer DiseaseAlzheimer's Disease

Locations1 site

Columbia University Irving Medical Center
New York, New York, 10032
Diana S. Guzman212-305-9079dsg2158@cumc.columbia.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.